Health inspection·March 14, 2025

F 0684 Provide appropriate treatment and care according to orders, resident’s preferences and goals. Level of Harm - Minimal harm or potential for actual harm Based on observation, interview, and record review, the facility failed to ensure, for five of five residents reviewed (Residents 1, 4, 5, 6, and 7) received medications timely, when Residents 1, 4, 5, 6, and 7 ' s scheduled 9 a.m. medications were administered to the residents passed the required timeframe. Residents Affected - Some This failure had the potential for the residents to experience discomfort, and a delay in the intended therapeutic effect of the medications. Findings: On February 25, 2025, at 9:25 a.m., an unannounced visit was conducted at the facility to investigate a complaint regarding quality of care. On February 25, 2025, at 11 a.m., Resident 1 was observed sitting up on the edge of bed. In a concurrent interview, Resident 1 stated she had some missed medications in the past. Resident 1 further stated the main medication she cared about was her Ritalin (methylphenidate - medication to treat used to treat attention deficit hyperactivity disorder). On February 25, 2025, at 1:30 pm, a concurrent interview and record review was conducted with the Director of Staff Development (DSD), and Licensed Vocational Nurse (LVN) 1. LVN 1 stated Resident 1 ' s Medication Administration Record, indicated the following medications scheduled at 9 a.m., on February 8, 2025, were administered to Resident 1 at 1:15 pm p.m. by LVN 2: - Amlodipine (medication to treat high blood pressure) 5 mg (milligram - unit of measurement); - Ascorbic acid 500 mg; - Cardizem (LA - long acting) (medication to treat high blood pressure) 300 mg; - Docusate sodium (medication to treat constipation)100 mg; - Duloxetine HCL (medication to treat nerve pain) 30 mg; - Famotidine 20 (medication to treat excess stomach acid) mg; - Ferrous sulfate (medication to treat anemia [a condition in which the body does not have enough healthy red blood cells or hemoglobin]) 325 mg; (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 3 Event ID: 056328 Printed: 05/15/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 056328 B. Wing A. Building (X3) DATE SURVEY COMPLETED 03/14/2025 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Premier Care Center for Palm Springs 2990 East Ramon Road Palm Springs, CA 92264 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)